Clinical Trials
23 trialsNCT07594106 2026-05-18
REGN15505 (PSMAx4-1BB) Alone or in Combination With Cemiplimab or REGN4336 (PSMAxCD3) in Adult Patients With Metastatic Castration-Resistant Prostate Cancer and Clear Cell Renal Cell Carcinoma
Regeneron Pharmaceuticals
Phase 1/2 Not yet recruiting
NCT06826768 2026-05-08
A Ph Ib Study of REGN5678 Plus Cemiplimab in Patients With mCRPC
M.D. Anderson Cancer Center
Phase 1 Recruiting
NCT07188896 2026-05-01
A Randomized Trial of Fianlimab and Cemiplimab +/- Ipilimumab or Ipilimumab Plus Nivolumab in First-line Advanced Renal Cell Carcinoma (RCC)
Hoosier Cancer Research Network
Phase 2 Recruiting
NCT07414992 2026-05-01
A Study of Radiation Therapy and Cemiplimab With or Without Fianlimab In People With Bladder Cancer
Memorial Sloan Kettering Cancer Center
Phase 2 Not yet recruiting
NCT06413680 2026-04-28
BrILliance
Regeneron Pharmaceuticals
Phase 1/2 Recruiting
NCT06699602 2026-03-04
A Study of Cemiplimab and Fianlimab in People With Clear Cell Renal Cell Carcinoma
Memorial Sloan Kettering Cancer Center
Phase 2 Recruiting
NCT07223541 2026-03-02
LAG-BOOST
University of Oklahoma
Phase 2 Recruiting
NCT04989946 2026-01-28
Androgen Deprivation, With or Without pTVG-AR, and With or Without T-Cell Checkpoint Blockade, in Patients With Newly Diagnosed, High-Risk Prostate Cancer
University of Wisconsin, Madison
Phase 1/2 Recruiting
NCT06022029 2025-12-24
ON-5001
OncoNano Medicine, Inc.
Phase 1 Recruiting
NCT04157985 2025-12-11
Evaluating Length of Treatment With PD-1/PD-L1 Inhibitor in Advanced Solid Tumors
University of Pittsburgh
Phase 3 Completed
NCT06052852 2025-11-17
Study of BDC-3042 as Single Agent and in Combination With Cemiplimab in Patients With Advanced Malignancies
Bolt Biotherapeutics, Inc.
Phase 1 Terminated
NCT03972657 2025-11-06
A Trial to Find Out if REGN5678 (Nezastomig) is Safe and How Well it Works Alone or in Combination With Cemiplimab for Adult Participants With Metastatic Castration-Resistant Prostate Cancer and Other Tumors
Regeneron Pharmaceuticals
Phase 1/2 Recruiting
NCT04954599 2025-10-07
Phase 1/2 Clinical Trial of CP-506 (HAP) in Monotherapy or With Carboplatin or ICI
Maastricht University Medical Center
Phase 1/2 Recruiting
NCT06571708 2025-09-02
NeoSTOP-IT
Columbia University
Phase 2 Recruiting
NCT05259696 2025-08-20
GLIMMER-01
Palleon Pharmaceuticals, Inc.
Phase 1/2 Completed
NCT05864144 2025-08-15
A Study of SNS-101 (Anti VISTA) Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid Tumors
Sensei Biotherapeutics, Inc.
Phase 1/2 Active not recruiting
NCT07101822 2025-08-03
BRAVA PENILE
Hospital Israelita Albert Einstein
Phase 2 Not yet recruiting
NCT03477864 2025-04-29
Stereotactic Body Radiation Therapy With REGN2810 and/or Ipilimumab Before Surgery in Treating Participants With Progressive Advanced or Oligometastatic Prostate Cancer
Thomas Jefferson University
Phase 1 Withdrawn
NCT03951831 2025-04-25
REGN2810 Followed by Chemoimmunotherapy for Newly Metastatic Hormone-sensitive Prostate Cancer
Columbia University
Phase 2 Active not recruiting
NCT04382898 2025-03-20
PRO-MERIT
BioNTech SE
Phase 1/2 Terminated
NCT05429866 2023-03-08
Immunological Variables Associated to ICI Toxicity in Cancer Patients
Jules Bordet Institute
Phase 2 Unknown
NCT03294083 2022-10-27
A Study of Recombinant Vaccinia Virus in Combination With Cemiplimab for Renal Cell Carcinoma
SillaJen, Inc.
Phase 1/2 Active not recruiting
NCT03367819 2022-05-16
Isatuximab in Combination With REGN2810 (Cemiplimab) in Patients With Advanced Malignancies
Sanofi
Phase 1/2 Terminated